Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hmmm, funny STS, never knew V had to pass through the stomach so it could be absorbed by the Large and or small intestines..... I thought your inestines all worked in concert????
Kind of like when I eat spicy Kimchee, I can't get to the bathroom fast enough, the stuff goes right through me like an express train..... :D)
Retired: Great analogy of comparing ARRY to AMRN. ARRAY Pharmaceuticals trading at $15+, Cancer drugs mainly, 197M shares outstanding, Revs through June 2017 $150M, Market Cap $2.6B. Heck, Amarin hit $185M revs for 2017, yet it's PPS is in the dirt (still).
My 30 second look and major takeaway from looking at Array, is they have multiple drugs, multiple collaborations with BP. This could be an indicator for Amarin as well and for impatient investors. Amarin's Go it alone, single drug platform has needless to say, been it's Achilles heel.
But oh my, when the results come in and they will be here before we know it, then the doors get blown off. Amarin can then develop multiple drugs based off Vascepa. Crawl before we walk, walk before we can run.
Frankly, I don't have any faith in the ITC nor the FDA doing the right thing towards Amarin. Sorry to say Amarin has only the courts to protect it's proprietary property. Any Agency that relies on Government employee subjectiveness (bribes) to decide the fate of companies is ridiculous and needs to be totally revamped. Never happen in my lifetime. Where this leaves Amarin (IMHO) is they will need to continue to take the fight to these agencies. An uphill struggle. Thero is a fighter. Even though Amarin has a strong case, doesn't insure victory or that the ITC or FDA will be swayed. Hence my illustration of the Boeing vs. Bombardier outcome decided by the ITC "Panel of Experts". Now Boeing has to file an Appeal with guess who? The courts.....
Not related to Amarin vs. ITC, but interesting decision by US ITC in Boeing vs. Bombardier. Boeing pleading it was harmed by Bombardier selling planes to Delta without paying tariffs.
https://www.bnn.ca/video/u-s-trade-agency-sides-with-bombardier-in-cseries-dispute-with-boeing~1313219
Strange how the minds work of government employees making multi-billion dollar decisions.
Yes, but Aurora isn't dumb enough to buy CMED shares in the open market especially now that its gone up 82% from $19? These are the times where you really got to have faith in your CEO (Booth) to do the right thing and not trade the farm for those magic beans. So, the folks still holding CMED shares are in the sweet spot. No longer do they have to settle for $24 per share. Just sell the shares on the Open Market instead of handing them over to a Transfer Agent. Either way shareholders who trade in their shares are made whole in the end.
Is CMEDs business really that accretive to sales? How many customers are we talking about, millions or thousands? In the end it's always about customer base.
Who's to say Aurora couldn't buy this technology and develop it themselves cheaper? Doesn't seem to be Aurora's MO.
Thanks HBG; whew CMED stock is up 6.5% $34.70, hopefully the deal won't drain the $$coffers$$, got to leave some cash for buildouts and M&A. CMED deal is getting more expensive. Wonder if it's too late to walk away? It's like chasing a stock on an upward trend..... keep changing the limit order.
Geez.... heavens no, I wanted to inject some humor into this board. Everyone seems so serious.... :D).....
The actual growing space would double if & when the merger goes through. If this is all the capacity CanniMed has, then Aurora must see value in CanniMeds, production facilities, capsule production and what's in their pipeline. There's more info on CanniMeds website. Pretty interesting stuff. The Newstrike deal may have added more production capacity. However, we don't know what's going on behind closed doors at the moment. Like someone said, if the CanniMed/Newstrike deal goes through, it could be a reefer (oops....threefer!) to coin a phrase. Newstrike/CanniMed/Aurora, one big happy family.
According to their website, not sure how old the info is; CanniMed has a total of 247,000 sq. ft. it's broken down like this.
Facility 1: Saskatoon, Saskatchewan 97,000 sq.ft. above ground, containing 30 growth chambers with a total growing capacity of 7,000 kg (annual?). A 2nd building with a 96,000 sq. ft. Administrative, shipping & distribution, R&D, hot tubs, titty bars, some employee bong rooms etc..... )(total 193,000 sq. ft.)
Facility 2: White Pine, Michigan, 35,000 sq. ft. office and production space; 19,000 sq. ft. of underground growth chambers currently under construction. (total 54,000 sq. ft.), bringing the total to 247,000 sq. ft.
I don't blame CanniMed for being a little secretive, this is a competitive market. However, I would like to know what I'm buying. I'm guessing maybe upwards of 200 employees, 100 of which are scantily clad cocktail waitresses, serving drinks and keeping those bongs loaded..... :D)
Can anyone tell me the size of CanniMed? Employee count, Production facilities (sq. ft.), Yahoo doesn't post this info and their (CanniMed) website is very non-descript. A sign of poor communication. One thing Aurora does well is communicate what it's doing, how big they are, how much they're growing, lots more PRs which is very important to investors. Aurora is not over the top, they post only pertinent PRs, I'm very impressed.
TIA,
Nuke
I know, I'm lazy, but I'm also busy and at work. Anybody know how many employees and the size of CanniMeds Production facilities are?
TIA,
Nuke
I like how the media especially Globe News comes out with Newstrike shareholders agree to be taken over. The proof will be will the CanniMed shareholders go along? If not, then Aurora can move ahead.
I mean really what do the CanniMed shareholders expect from inept management? You learn to live with bad management or you change it. Hopefully, the shareholders can see that after all of this has come out.
Either lead, follow or get the hell out of the way. CanniMed (Zettl) CEO needs to get out of the way.
Salomon, agree 100% with your assessment of Cannimed leadership. They have failed their shareholders. Today's business world is either " eat or be eaten"
You're clueless, once marijuana is legalized, the mj market will grow exponentially. Why? Because mandatory drug tests for employment and random screening for cannabinoids will not be enforceable. Sobriety testing for alcohol yes, but for cannabinoids no. Watch
You're clueless, once marijuana is legalized, the mj market will grow exponentially. Why? Because mandatory drug tests for employment and random screening for cannabinoids will not be enforceable. Sobriety testing for alcohol yes, but for cannabinoids no. Watch
Laura, The one thing to remember is that we're all (Longs) in this together. We're almost home, we can see the light at the end of the tunnel. You've been in this investment for five years or more is a testament to your patience, don't lose heart while we're so close to the seeing the end.
Those of us who have been able to afford and take Vascepa, know it's effects. The reason for continued Scripts increase is a undeniable proof that Vascepa is effective in treating a myriad of symptoms.
My only advice, if you choose to accept it is, "DO NOT SELL" stay the course.
Take care,
Nuke
STS:
#1 IMHO we're already seeing that V works, with real RWE data. Why else would there be increasing scripts and market share? Wouldn't you think that Docs, clinicians are seeing positive results from their existing patients and prescribing it to other patients? Word of mouth advertising is alive and well.
#2 I didn't attend the JPM Conference, but on Stocktwits I saw a couple of posters who did attend and said they could tell from John Thero's body language and confidence level that something good is happening with V. Apparently there were like 400+ Investment Bankers in attendance and that Thero got quite a round of applause after his presentation.
#3 Other intangibles that you don't often see especially with small companies, is Amarin Management coming out with a preliminary financial reports. I guess I've been asleep all these years, but that is the first time I've ever seen anything like that before.
#4 Don't shoot me, but, the PPS hasn't cratered Post Conference, in the past it has, not saying it won't just that it bespeaks higher lows and eventually higher highs.
#5 March begins an end to the R-It, saving cash. How many small cap Biotechs can boast being profitable and reducing their cash burn like Amarin has? Too many good things are happening. Maybe just maybe we’ve seen that last of sub $4 levels?
Hi Kiwi, glad to see you're hanging in there. Sorry about not responding right away, still on Posting sanctions (one Post per day limitation).
A fellow van rider is on Vytorin, she swears by it. Expensive but insurance covers most of the cost.
Talk about a combo pill, how about V, a statin, Ezemtibe and a blood pressure med all wrapped into one capsule with varying strengths depending upon your tolerance levels?
I would just take Vascepa and be done with it, keep things simple.
Investment in Canadian Cannabis; I bought Aurora (ACBFF), actually did a really quick DD of Canopy, Aphria and finally chose Aurora because it was the most aggressive and least expensive (bot @ 5.42). Go big or go home. Once the CanniMed deal (CMED) acquisition is done, Aurora becomes a Big Dog, plus I like what the management is doing (conserving cash). Once the CanniMed deal is done, I look for Aurora to get into the high teens, even with the stock dilution. CanniMed will be immediately accretive to Sales as the revenue from the combined companies will essentially double. Plus, I look at the offer price Aurora is making for CMED shares ($24). rising water raises all boats.
I sold half my ACBFF investment @ 8.07 and dug my profits back into Amarin. I got this hunch that Amarin will be the Big Dog we all hope it will be. My guess for PPS post RI? I'm thinking more like $15 Post RI (400%). Wishful thinking? Don't think so, as Amarin has been here before. After RI proves Vascepa efficacy, then we move really fast and strong. My only concern is cash needed for expansion. What does Amarin give up for the needed cash? Sales are good but too slow to provide the cash needed to capture market share. If you have a high demand and cannot supply that demand, people go elsewhere.
I won't comment on ITC, hopefully the court will decide what is just and rule in Amarin's favor. I can't depend upon government agencies to make things right.
Regards,
Nuke
Hate to rain on anyone's parade; IMHO where is Amarin going to get the money to build out Post RI to support the following?
1) Increase Sales force and staff
2) Increase production
3) Increase advertising
4) Increase R&D
With only $73 million in cash, something needs to happen. The money for expansion has to come from somewhere. With Amarins "go it alone" mindset, IMHO they won't be able to pull this off without a cash infusion.
Believe me, it will be nice to see scripts in the 40 million range, but without the cash to support this kind of build-out, I can only "conjecture" what Amarin has to do to increase sales by 1000%. Going from 150K in scripts to 40M in scripts requires cash plain and simple. Or heaven forbid a Big partner. If there's no buy-out (Amarin GIA), then what?
If this has already been discussed then I apologize. It definitely is a good position to be in (increased sales), but in today's world it's either eat or be eaten. Case in point look at the Canadian Cannabis market.
As soon as we get rid of the weak sellers, Amarin should continue trending up going into the JP Morgan Conference next Wednesday. Historically, it's gone up every time I recall during Dog & Pony shows. Every time I wanted to sell and never have, it's gone down. Only this week, I wanted to sell some shares, but, lo and behold it's gone up??? I do not think folks who want to sell and take money off the table is a bad thing..... as long as they don't have a hidden agenda like some posters who have come and gone.
Long and strong Amarinites
AMRN posts preliminary Earnings report;
https://www.etrade.wallst.com/v1/stocks/news/search_results.asp?docKey=1-SN20180104007247-6NFOOD5J1RLB0BLG00F9GHKL2K&DMSourceID=GlobeNewswire&Source=GlobeNewswire&docDate=2018-01-04%2021:30:00&headline=Amarin%20Provides%20Preliminary%202017%20Results%20and%20Provides%202018%20Outlook&refSymbols=US;AMRN
Highlights: Should be a good up day tomorrow, but then again we've seen the opposite;
Amarin Provides Preliminary 2017 Results and Provides 2018 Outlook
4:30 PM ET 1/4/18 | GlobeNewswire
Amarin Provides Preliminary 2017 Results and Provides 2018 Outlook
Unaudited Full-Year 2017 Net Product Revenue Estimated Between
$177 and $180 Million, Exceeding Upper End of Previously Provided Guidance,
with Fourth Quarter Estimate Between $51 and $54 Million
Anticipate 2018 Net Product Revenue Growth of Approximately
$50 Million or $230 Million for Full-Year 2018 Net Product Revenue with Guidance
to Be Updated After REDUCE-IT Results, Expected Before End of Q3 2018
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today provided a business update, including an update on 2017 revenue guidance, 2018 revenue forecast and potential 2018 milestones. Amarin plans to discuss these results and expectations with investors in connection with the 36(th) Annual J.P. Morgan Healthcare Conference in San Francisco, California, at which Amarin will be presenting.
Preliminary (unaudited) 2017 Financial Results
Record Revenue Levels: Net product revenue for 2017 are estimated to have reached between $177 million and $180 million, including estimated net revenues of $51 million to $54 million in Q4 2017. Both the full year and Q4 2017 results represent record revenue levels for Amarin. These results, which are subject to audit, are estimated to have exceeded the upper end of the company's previously reported guidance for 2017 net product revenue and represent an increase of approximately $48 million to $51 million (approximately 37% to 40%) over full year 2016 results. Both full year and Q4 2017 net revenue growth were driven by increased prescriptions for Vascepa(R) (icosapent ethyl) capsules. Wholesaler inventory levels of Vascepa were within normal industry ranges at the end of 2017.
Balance Sheet: Amarin ended 2017 with approximately $73.6 million in cash, approximately $44 million in net accounts receivable and approximately $29 million in inventory. During 2017, the company's net cash outflows, excluding the $13.7 million net proceeds of exchangeable debt transactions disclosed in Q1 2017, were approximately $38.4 million, comprised of net cash outflow in Q1, Q2, Q3 and Q4 of approximately $15.9, $10.6, $6.4 and $5.5 million, respectively. The company believes that it was effective in 2017 in controlling its cash expenditures to achieve greater contribution from the growing revenues of its commercial operations. The company achieved its stated objective of being net cash flow positive in 2017 after excluding, on a non-GAAP basis, the net proceeds of the Q1 2017 exchangeable debt transactions and excluding greater than $40 million of payments for R&D (primarily REDUCE-IT related) and approximately $17 million of payments for financing-type costs (e.g., interest and royalties).
The company's accounts receivable were all current as of year-end and the company has not factored or otherwise borrowed against accounts receivable, inventory or other assets. Due in part to recent U.S. tax reform, Amarin anticipates further increasing its valuation allowance against deferred tax assets in Q4 2017, which will result in a non-cash charge for income taxes of as much as $11.1 million. The deferred tax assets relate to the company's U.S. subsidiary. The valuation allowance does not change the amount the company pays in income taxes and does not have any impact on the company's tax loss carryforwards, primarily in Ireland, which are estimated at over $570 million at the end of 2017. At the end of 2017, the company's debt consisted of $30 million face value of exchangeable debt, which cannot be put to the company before 2022, and the continuing 10% royalty-like obligation on Vascepa net revenue.
Gross Margin: In addition to the company's increased revenues and improved cash flow, in 2017 Amarin also increased its gross margin on product sales to approximately 75% while taking steps to ensure that it has capacity to support a broad-range of potential revenue scenarios following REDUCE-IT results, including capacity to provide supply to support the potential of over $1 billion in product revenues in 2019. These steps to expand supply capacity are intended to provide the company with flexibility to support business growth. At this time, the company is not providing guidance regarding projected Vascepa net revenue levels after REDUCE-IT results and does not plan to provide such guidance until after the results of this important study are known.
More than 150,000 patients currently benefit from Vascepa prescriptions.
2018 Financial and Operational Guidance
Amarin's core strategy entering 2018 remains unchanged. Its primary objectives are as follows:
1) Continue to aggressively grow revenues;
2) Complete the REDUCE-IT study on a timely basis while maximizing the likelihood of success; and
3) Operate in a cost-effective, opportunistic manner.
The company's outlook for 2018 is divided between the timeframes before and after anticipated results of the REDUCE-IT cardiovascular outcomes study. REDUCE-IT, which has been the centerpiece of the company's strategy, is expected to be completed in 2018 with top-line results reported before the end of Q3 2018. The degree of cardiovascular relative risk reduction achieved in this study will impact future levels of Vascepa promotion and revenues. Assuming that statistically significant relative risk reduction of at least 15% is achieved and, as expected, there is no major negative safety issue, the company intends to expand its U.S.-based sales force promptly after the outcomes study results. As previously disclosed, Amarin is planning to grow from its current level of approximately 150 sales representatives calling on targeted physicians in limited geographies, to more than 400 sales representatives with considerably broader reach and increased frequency of sales calls. Amarin plans to support this sales force growth with increased promotional outreach to consumers and other expanded promotion of Vascepa.
Thanks Seconway;
Populations aside, nice markets to get into....
Denmark Pop 5.73 million
Sweden Pop 9.90
Norway Pop 5.23 million
Not that Janvik the reindeer herder will ever toke up while herding in subzero weather remains to be seen. These governments need this product so it can be taxed and added to their coffers. Plus it lowers their cost of drugs and socialized medicine.
Unbelievable, Zettl CEO of Cannimed is such a dick. He needs to go for sure. He has bungled Cannimed for too long. He has the huevos to call the 105 grace period a victory? What a fool. What is he expecting? To stop the Aurora train?7
JL; is that from Jesse Livermores book too? Can't say as I've ever heard that before.
Ever think to wonder Aurora is reserving their cash for something else?
Could be the dilution will be short lived?
I do believe in keeping your core business in focus. I don't understand when companies, especially relatively small companies like Aurora start doing divestitures into other companies and sectors like Radient and Micron Waste (MICWF). Does Aurora want to be a Grower or what a paraphenalia supplier Radient? I'm not upset so much with them buying CannaMed as this is part of their core business.
Too many fingers in the pie and you're never able to grab a bite.....
Hi JL; Fancy meeting you here. Bought into ACBFF a couple weeks back. Very interesting.......
Nuke
I think I saw his name from some movie credits on "HeartBreak Ridge" St. Georges Medical School in Grenada fame? His name was in the credits as being a stunt double for "Stitch Jones" during the assault on the Fort.
He was also one of the Cubans soldiers inside the Fort, when the hand grenade was thrown in. A guy's got to make a living some how and get through med school. He may have been in the shower scene as well.
Love your hindsight: Meaningless unless you are a stock historian. That's like saying; Birkshire Hathaway was selling for $1000 in 1964, why didn't we buy it instead?
https://www.investopedia.com/articles/markets/020916/if-you-had-invested-right-after-berkshire-hathaways-ipo-brka.asp
I think what we're going to see with Amarin is an exponentially Cataclysmic explosion similar to Yellowstone National Park. Once the reports backed up by science begin to emerge, there's no stopping Amarin. Plus if the FDA is uncooperative (As stupid as they are), Amarin will launch a legal barrage. This will not be another ADCOM, not with all the preponderance of data supporting EPA.
Bio: Let's think about this for a minute.... ok minutes up...Let's look at Amarin's historical approach to being knocked around. Amarin was knocked down hard in round 1 at ADCOM. They got up off the mat and didn't quit did they? FDA then pulled the rug out rescinding the SPA, knock down #2. Did they quit? No my friend, they said hit me again, like Rocky Balboa vs. Apollo Creed. Were they done yet? No way... Amarin Management chooses their battles. 1st Amendment, I've forgotten the other. They've definitely shown their mettle. They've chosen a good law team. Amarin and their Legal team are hard at work. It doesn't hurt however to have a "Joe the Plumber" beating the drum... if you get my drift. God knows I don'have the energy nor the time to do anything but watch the story unfold.
I do believe Amarin Management is doing the best it can under the circumstances for themselves and the shareholders. They are fighters. They've proven that.
Bio: Me thinks your tilting at Windmills my friend.
SEC investigate anything? Does Bear-Stearns ring any bells? No wait that was another Gubmint Agency, the Federal Reserve, dang they all have their fingers in the pie....hope it's Blackberry....
What ever happened to the OxyCotin debacle? Anybody hear anything yet?????
cheep, cheep, cheep.......(the sound of crickets)
How about them AZ Cardinals? 33-0 loss to the Rams, lose their quarterback, who knows maybe they'll start playing better this week?
Bio; Ever see the movie "Rainmaker" with Matt Damon, Danny Devito and a stellar cast? Movie is about an Insurance Company who refused to pay a cancer victims hospital bills etc. (Fiction of course). Although I have see real life deals get settled on the golf course since it would have bankrupted the company that was in the wrong.
If Amarin does get its justification and can receive damages from the offending companies, then it will be a short term thing. Who's to say these companies won't declare bankrupcty, change their name and start all over again. It's our screwed up justice system that allows this.
GLT you my friend, we'll all need it.
STS; wait and see.... Yes, I was here prior to "ADCOM Ambush" I was thinking Vascepa was a slam dunk.....NOPE!
I don't disagree with 60 Minutes TV Show being a powerful media purveyor, just look at who's involved and how many fingers are in the pie. Health Care Providers, Congress, FDA, DEA, President Obama. Really would like to see something happen to the constituents, but there's too many to name.
The shame of it all is that people care more about cruelty to animals than they do human beings. Someone dies of a drug overdose..... so what? A dog is run over in the street, starved to death or used in dog fights (Ask Michael Vick!). Dogs and cats sleeping together? Public goes insane.
What we need is a Robes Pierre, set up the guillotine and start lopping heads.
STS; watch how fast this gets swept under the carpet. Big money is in control. Congress and FDA are just pawns. Things like this is the reason John F and Robert F Kennedy were shot. Ever hear of any quantifiable investigations worth a dam resulting from their assassinations?
Money talks....
Congress and the FDA walk away unscathed.... watch and see.
You now know what Donald Trump is up against
Pissed off Nuke
I thought it might be a new Sea food using Polyps instead of scallops. You know these Foodies, they always got to try something weird and different.
What kind of wine is suitable do you suppose? Red or White?
Lab; be careful, Houston still flooded..... I'd be wearing a nuisance (dust) mask just to keep the bad microbes out, plus long sleeves for the skeeters. They say they can pick up small children.... good luck and a tip o the cap to you....
"Nukel Head"
http://wgntv.com/2017/09/12/tests-reveal-extremely-toxic-floodwater-in-houston-after-hurricane-harvey/
Congrats Louie; one problem is time my friend..... thinking we have a couple years before Amarin hits the big time. We shall see in about 12 months when R-It comes out.
Going on 34 Years myself in Nuclear Power (quasi-government), so, I understand your feeling.
Anybody see SAM81? Kind of going through withdrawal not seeing the latest script numbers....
Take care,
Nuke
Production of Omega 3s from Algae; fairly recent report dated October 2016
http://www.oilgae.com/ref/report/non-fuel-algae-products.html
Interesting excerpt from the Key Takeaways section.
Pharmaceuticals are the fastest growing section of the market, but as yet there are only two approved omega 3 based pharmaceuticals in the world, which together account for 1.6% of consumption with nearly US $ 1.5 billion in sales. Other EPA and DHA based triglyceride reduction products are under development, but it will take some time before these achieve regulatory approval and eventual commercialization
The current wholesale market price for algae omega-3 oil is about US$ 140/kg which is higher than the pricing for fish oil derived products. The Global Organisation for EPA and DHA and Frost and Sullivan (2010) estimated that the global market for EPA and DHA omega-3 oils exceeded 85,000 t in 2009 and was estimated to grow to 135,000-190,000 t by 2015
Nearest company that may be producing DHA, EPA is a Chinese Corp, (BGG)
Cost you $900 to find out more..... :D(
Personally, I'd like to talk about tomorrows earnings. Rather than blather all day about possibilities of stoppage. Seriously Folks, this gets old. Who cares if they stop or not. In the long term scheme of things it doesn't really matter, we will get there eventually. IMHO, I'd rather see Reduce-It go the distance. "Build it and they will come." one of my favorite movie lines of all time. Amarin has built quite a Patent Moat, complete with Crocodiles, Water moccasins and Lawyers.....err I mean Leeches.....
Good luck tomorrow y'all
Numbskull Nuke
RetiredCEO; I took your suggestion and watched "The Big Short" last night. WOW! Great movie. I didn't realize the intricacies involved and nobody went to jail..... no one.....!!!! Madoff was the scapegoat, later....
How this plays in Biotech is no different really..... Companies sponsor studies and ensure they're data is good or will appear to be good on the outside, packaged in a way to confuse and befuddle even the most discerning. Health care doesn't want the truth they want something that sells and looks enticing. Example: Obama Care, not going into that, but why do I have to pay insurance premiums at all if I'm relatively healthy with no family history.... It's mandated.
How this sick system of ours effects healthcare and Amarin in particular?
> There's no room for innovation, especially for small cap companies
> You must play the game, Amarin Mgt. refused to play the game, therefore they got a bad rep, for what? Being truthful and beyond reproach?
> We'll tie you up in courts if we don't get what we want.
> We'll attack your patents, just try and stop us. (aka QUALCOMM vs. Apple debacle).
> You want five (5) year NCE? We'll show you Amarin..... (enter the FDA), we'll make your life miserable.
> Valuation, what for? Our moneys on Pre-clinical cancer companies with no products in the pipeline, but they sound good don't they?
I'm so pissed off with my Government, been that way for a long time, worked fifty years for what? So my FICA taxes can be paid to those who didn't lift a finger? Study up on "Net Neutrality", this has far reaching consequences for our society. Freedom for all, even for those that don't feel they should have to pay for goods or services. Where does this all lead? If the Generics feel they want to produce and market purified EPA, what's to stop them. Does Amarin have such deep pockets that they can afford to litigate all these patent infringements?
I'm not short you all know this, just that I can see what's coming down the pike and it doesn't look good. Amarin needs a White Knight. Sorry to say they'll need to form a partnership at the very least. Buyout would be better. Going it alone? I can see where that's headed. Amarin doesn't have enough money. Reduce-it outcome? As a long, I know the numbers will be good, I don't want to venture a guess as it erupts into an endless diatribe.
Nuff said,
I love Tabasco? Don't tell me they're going to be pulling from the shelves? Just kidding... :D), agree with your assessment. Deep pockets can do just about anything. Bribery, deceit, false reporting. Now, if they could combine EPA with Tabasco,then you would have a Blockbuster. A heart drug that prevents tapeworm.
Thanks SAM81 and Zumantu;
Great numbers SAM..... please explain what Sector % means, thanks
Zuman: It's really unfortunate studies like this fall on deaf ears at the FDA. During the ADCOM (Kangaroo Court), when Amarin brought up JELIS study, I got a sense of racial prejudice along with "I don't care what JELIS results were attitude from the FDA" Enough on that.... So, bottom line, having platelets form after a stent implant is a bad thing because they form into clots? I did get the EPA/AA ratio, the results from 31 patients with these types of results from administering a 1.8 gms of EPA is great. imagine what 4 gms per day will do? What's with these Japanese studies, seems like they like using 1.8 gms doses??? Has there been any Japanese studies that used higher EPA dosage? TIA
Nuke
Thanks rydad;
Here's an article about Qualitas, New Mexico and Texas. I thought there was another company out of Australia or New Zealand that Zoogoddess posted many moons ago... Started with a "P" photonics or something like that.
And why not get EPA from Algae, that's what the fish do, besides eating each other.
picasel.... a threefer....
> #1 Go to Post # 109565 CJR_MS posted the script numbers for 6/30
> #2 Great post JL, so we should see a Placebo rtae somewhere close to 5.9%. As Bill & Ted would say (Bill & Ted's Famous Adventure) EXCELLENT.....
> #3 and Lastly, tell our mutual friend BioBill to stop responding to ol what's his name, the uninformed one, with an agenda. He's giving us old timers heartburn. Besides if he keeps this up tell him I have a Bridge in Brooklyn to sell him.
> #4 Have a great weekend all, Amarin appears to be holding it's own, good to see it stabilize @ 4.24 range, this morning was an obvious Stop loss mousetrap. Looks like it worked.
Nukel Head